We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
RBC Capital Markets analyst Randall Stanicky sees lots of reasons Allergan should pursue a breakup. A women’s health sale that could bring in billions is just one of them.